Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBITDA: 2010-2025

Historic EBITDA for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to -$94.9 million.

  • Iovance Biotherapeutics' EBITDA fell 6.55% to -$94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$416.5 million, marking a year-over-year increase of 3.14%. This contributed to the annual value of -$395.3 million for FY2024, which is 14.17% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its EBITDA stood at -$94.9 million for Q3 2025, which was up 16.59% from -$113.8 million recorded in Q2 2025.
  • Iovance Biotherapeutics' EBITDA's 5-year high stood at -$86.6 million during Q4 2024, with a 5-year trough of -$121.3 million in Q4 2023.
  • Its 3-year average for EBITDA is -$107.8 million, with a median of -$110.9 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first grew by 28.60% in 2024, then fell by 11.64% in 2025.
  • Iovance Biotherapeutics' EBITDA (Quarterly) stood at -$121.3 million in 2023, then rose by 28.60% to -$86.6 million in 2024, then declined by 6.55% to -$94.9 million in 2025.
  • Its last three reported values are -$94.9 million in Q3 2025, -$113.8 million for Q2 2025, and -$121.2 million during Q1 2025.